We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Immunophenotypic Evaluation of IL-7R α in Acute Leukaemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05643547
Recruitment Status : Not yet recruiting
First Posted : December 8, 2022
Last Update Posted : December 8, 2022
Sponsor:
Information provided by (Responsible Party):
Rania Abdeltwab Abdelazeim, Assiut University

Brief Summary:

Acute leukemia is generally understood to be a neoplastic process that exerts a maturational block at a hematopoietic precursor cell level, accompanied by a proliferative drive of varying degree. The resulting accumulation of cells, most frequently in the marrow, causes the typical clinical picture, which includes marrow failure, tissue infiltration, organomegaly and on occasion, tumor masses. AL is broadly classified as acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) (1).

Acute lymphoblastic leukemia is frequently diagnosed in children and young adults, with incidence peaks between 2 and 5 years of age (2), whereas AML is the most common acute type in adults (3).

In addition to leukemia cells themselves, cells of the immune system are a fundamental component of the tumor microenvironment (TME), which often modify the TME to be more favorable to tumor development and progression through producing cytokines and mediators (4,5) . Interleukins / interleukin receptors interaction plays important roles in the antitumor immune response through mediating cell-cell communication in TME and is reported to be relevant to patient prognosis (6,7). As a member of the Interleukin family, Interleukin 7 (IL7) play vital roles in hematopoiesis and the development of T lymphocytes, as well as the inflammation, autoimmune diseases and hematological cancers. Its function is mediated by the IL7 R, which is a membrane receptor consisted of the specific IL7Ra chain (CD127) and IL-7Rγ chain (common gamma chain shared by the receptors for IL-2,-4,-9,-15, and-21) (8). It is thus not surprising that activation of IL-7 signalling is seen in the majority of T-ALLs and in some of the B cell precursor ALL (9,10).

Consistent with the absolute requirement of IL-7 to human T cell development, most T-ALLs have been shown to respond to IL-7. Thus targeting IL-7 signaling might be a reasonable general approach for treatment of T-ALL, regardless the presence of activating mutations. (10)


Condition or disease
Benefit: To Patient Have Investigation for Diagnosis and Follow up for His Disease and Reach to New Method Help in Early Diagnosis of Lymphoid Disorder

Detailed Description:

Acute leukemia is generally understood to be a neoplastic process that exerts a maturational block at a hematopoietic precursor cell level, accompanied by a proliferative drive of varying degree. The resulting accumulation of cells, most frequently in the marrow, causes the typical clinical picture, which includes marrow failure, tissue infiltration, organomegaly and on occasion, tumor masses. AL is broadly classified as acute myeloid leukemia (AML) and acute lymphoid leukemia (ALL) (1).

Acute lymphoblastic leukemia is frequently diagnosed in children and young adults, with incidence peaks between 2 and 5 years of age (2), whereas AML is the most common acute type in adults (3).

In addition to leukemia cells themselves, cells of the immune system are a fundamental component of the tumor microenvironment (TME), which often modify the TME to be more favorable to tumor development and progression through producing cytokines and mediators (4,5) . Interleukins / interleukin receptors interaction plays important roles in the antitumor immune response through mediating cell-cell communication in TME and is reported to be relevant to patient prognosis (6,7). As a member of the Interleukin family, Interleukin 7 (IL7) play vital roles in hematopoiesis and the development of T lymphocytes, as well as the inflammation, autoimmune diseases and hematological cancers. Its function is mediated by the IL7 R, which is a membrane receptor consisted of the specific IL7Ra chain (CD127) and IL-7Rγ chain (common gamma chain shared by the receptors for IL-2,-4,-9,-15, and-21) (8). It is thus not surprising that activation of IL-7 signalling is seen in the majority of T-ALLs and in some of the B cell precursor ALL (9,10).

Consistent with the absolute requirement of IL-7 to human T cell development, most T-ALLs have been shown to respond to IL-7. Thus targeting IL-7 signaling might be a reasonable general approach for treatment of T-ALL, regardless the presence of activating mutations. (10).

Layout table for study information
Study Type : Observational
Estimated Enrollment : 83 participants
Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
Official Title: Immunophenotypic Evaluation of IL-7R α in Acute Leukaemia
Estimated Study Start Date : March 1, 2023
Estimated Primary Completion Date : December 30, 2023
Estimated Study Completion Date : October 30, 2024

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Leukemia




Primary Outcome Measures :
  1. Immunophenotypic expression of IL7R α in acute leukemia cases. [ Time Frame: 2022-2024 ]
    Immunophenotypic expression of IL7R α in acute leukemia cases.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Sampling Method:   Probability Sample
Study Population
- Newly diagnosed patients with Acute leukemia (ALL, AML), male or female at any age will be investigated for Immunophenotypic expression of IL7R α and its diagnostic value.
Criteria

Inclusion Criteria:

  • Newly diagnosed patients with Acute leukemia (ALL, AML), male or female at any age.

Exclusion Criteria:

  • Patients diagnosed with hematological malignancy other than acute leukemias
  • Patients receiving chemo and/or radiotherapy
  • Patients on steroid therapy for any other reason
  • Patients receiving any immunosuppressive drug
Layout table for additonal information
Responsible Party: Rania Abdeltwab Abdelazeim, Immunophenotypic evaluation of IL-7R α in Acute leukaemia, Assiut University
ClinicalTrials.gov Identifier: NCT05643547    
Other Study ID Numbers: 159159
First Posted: December 8, 2022    Key Record Dates
Last Update Posted: December 8, 2022
Last Verified: November 2022
Additional relevant MeSH terms:
Layout table for MeSH terms
Disease
Pathologic Processes